2-溴-1-[3-(苯基甲氧基)苯基]-乙酮 | 19381-40-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-1-[3-(苯基甲氧基)苯基]-乙酮
• 中文别名: 乙酮,2-溴-1-[3-(苯基甲氧基)苯基]-
• 英文名称: 1-(3-(benzyloxy)phenyl)-2-bromoethanone
• 英文别名: 2-(3-benzyloxyphenyl)-2-oxoethyl bromide；2-Bromo-1-<3'-(benzyloxy)phenyl>ethanone；m-benzyloxy-ω-bromoacetophenone；2-bromo-1-(3-benzyloxyphenyl)ethanone；bromomethyl 3-benzyloxyphenol ketone；2-bromo-3'-(benzyloxy)acetophenone；2-bromo-1-(3-phenylmethoxyphenyl)ethanone
• CAS: 19381-40-9
• 化学式: C₁₅H₁₃BrO₂
• 分子量: 305.171
• InChiKey: GFZOJLIHCWKKPR-UHFFFAOYSA-N

物化性质

• 沸点：
  395.5±22.0 °C(Predicted)
• 密度：
  1.394±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  2-溴-1-[3-(苯基甲氧基)苯基]-乙酮 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、413.69 kPa 条件下， 反应 48.0h， 生成 (2R,5R)-5-<2'-(3''-Hydroxyphenyl)ethyl>proline tert-butyl ester
  参考文献：
  名称：

  Conformationally Constrained Analogs of Anatoxin. Chirospecific Synthesis of s-Trans Carbonyl Ring-Fused Analogs

  摘要：

  Anatoxin is the most potent agonist known for the nicotinic acetylcholine receptor (nAChR). Although it possesses a semirigid structure, it can adopt four distinctly different conformations. Further conformationally constrained analogues of anatoxin should help to refine and discriminate among the current models for activation of this receptor. This report describes three s-trans ring-fused analogues which have been synthesized starting from D-glutamic acid and 3-hydroxyacetophenone. All of them have in common a 3-oxo-13-azatricyclo[8.2.1.0(2,7)]trideclane structure. They represent the first fully constrained analogues of anatoxin and are designed to serve as probes of the bioactive conformation of anatoxin at the acetylcholine nicotinic receptor site.

  DOI：

  10.1021/jo00084a023
• 作为产物：
  描述：

  3-苄氧基苯乙酮 在 溴 、 calcium carbonate 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以69%的产率得到2-溴-1-[3-(苯基甲氧基)苯基]-乙酮
  参考文献：
  名称：

  Efficient Asymmetric Hydrogenation of .ALPHA.-Amino Ketone Derivatives. A Highly Enantioselective Synthesis of Phenylephrine, Levamisole, Carnitine and Propranolol.

  摘要：

  吡咯烷双膦配体（CPMs）与铑（I）形成的复合物被发现是α-氨基酮 hydrochloride 衍生物的不对称加氢反应的高效催化剂。利用这一方法，我们开发了光学活性的β-氨基醇、苯肾上腺素、左旋咪唑、肉碱和普萘洛尔的高效不对称合成。

  DOI：

  10.1248/cpb.43.738

文献信息

• [EN] (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS<br/>[FR] DÉRIVÉS DE (THIO)MORPHOLINE MODULATEURS DE S1P
  申请人：ABBOTT HEALTHCARE PRODUCTS BV

  公开号：WO2011023795A1

  公开（公告）日：2011-03-03

  The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本发明涉及公式（I）的（硫）吗啉衍生物，其中R1从氰基，（2-4C）炔基，（1-4C）烷基，（3-6C）环烷基，（4-6C）环烯基，（6-8C）双环烷基，（8-10C）双环基团中选择，每个基团可选择地取代为（1-4C）烷基，苯基，联苯基，萘基，每个基团可选择地取代为一个或多个取代基，独立选择自卤素，（1-4C）烷基可选择地取代为一个或多个氟原子，（2-4C）炔基，（1-4C）氧烷基可选择地取代为一个或多个氟原子，氨基，二（1-4C）烷基氨基，-SO2-（1-4C）烷基，-CO-（1-4C）烷基，-CO-O-（1-4C）烷基，-NH-CO-（1-4C）烷基和（3-6C）环烷基，苯基取代为苯氧基，苄基，苄氧基，苯乙基或单环杂环烃，每个基团可选择地取代为（1-4C）烷基，单环杂环烃可选择地取代为卤素，（1-4C）烷基或取代为苯基的苯基，可选择地取代为（1-4C）烷基，和双环杂环烃可选择地取代为（1-4C）烷基；A从-CO-O-，-O-CO-，-NH-CO-，-CO-NH，-C=C-，-CCH3-O-和连接基-Y-（CH2）n-X-中选择，其中Y连接到R1并从键，-O-，-S-，-SO-，-SO2-，-CH2-O-，-CO-，-O-CO-，-CO-O-，-CO-NH-，-NH-CO-，-C=C-和-C≡C-中选择；n是1到10的整数；X连接到苯基/吡啶基团并从键，-O-，-S-，-SO-，-SO2-，-NH，-CO-，-C=C-和-C≡C-中选择；环结构B可选择地含有一个氮原子；R2是H，（1-4C）烷基可选择地取代为一个或多个氟原子，（1-4C）氧烷基可选择地取代为一个或多个氟原子，或卤素；R3是（1-4C）烷基-R5，其中烷基基团可取代为（CH2）2形成环丙基基团或一个或两个卤素原子，或R3是（3-6C）环烷基-R5或-CO-CH2-R5，其中R5是-OH，-PO3H2，-OPO3H2，-COOH，-COO（1-4C）烷基或四唑-5-基；R4是H或（1-4C）烷基；R6是一个或多个取代基，独立选择自H，（1-4C）烷基或氧代基；W是-O-，-S-，-SO-或-SO2-；或其药学上可接受的盐，溶剂或水合物；但是，公式（I）的衍生物不是2-（4-乙基苯基）-4-吗啉乙醇或4-[4-（2-羟乙基）-2-吗啉基]苯乙腈或其药学上可接受的盐，溶剂或水合物。本发明的化合物具有对S1P受体的亲和力，可用于治疗、缓解或预防S1P受体介导的疾病和症状。
• [EN] UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS<br/>[FR] COMPOSÉS D'URÉE ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME FAAH
  申请人：BIAL PORTELA & Cª S A

  公开号：WO2015016728A1

  公开（公告）日：2015-02-05

  A compound having Formula (I): wherein: R1 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R3 is C1-4 alkyl; R4 is aryl which is substituted with a group selected from OSO2NH2, NHCONH2, NHSO2NH2, NHSO2C1-4 alkyl and CONH2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methylsulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.

  具有以下化学式（I）的化合物：其中：R1从氢、卤素、羟基和C1-4烷氧基中选择；R2从氢、卤素、羟基和C1-4烷氧基中选择；R3是C1-4烷基；R4是芳基，其被从OSO2NH2、NHCONH2、NHSO2NH2、NHSO2C1-4烷基和CONH2中选择的基团取代；n为0或1；或其药学上可接受的盐；前提是该化合物不是N-(1-苄基哌啶-4-基)-N-甲基-4-(4-(磺胺氨基)苯基)-1H-咪唑-1-羧酰胺或N-(1-苄基哌啶-4-基)-N-甲基-4-(3-(甲磺酰氨基)苯基)-1H-咪唑-1-羧酰胺。该化合物可用作脂肪酸酰胺水解酶的抑制剂。
• 2,3-substituted indole compounds as anti-inflammatory and analgesic agents
  申请人：——

  公开号：US06608070B1

  公开（公告）日：2003-08-19

  This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

  这项发明提供了以下式的化合物： 或其药学上可接受的盐，其中Z为OH、C1-6烷氧基、—NR2R3或杂环；Q从以下中选择：(a) 可选择取代的苯基，(b) 可选择取代的含有一个、两个、三个或四个氮原子的6-成员单环芳基，(c) 可选择取代的含有O、S和N中选择的一个杂原子的5-成员单环芳基，并且除所述杂原子外还可选择含有一个、两个或三个氮原子，(d) 可选择取代的C3-7环烷基和(e) 可选择取代的苯并噻吩杂环；R1为氢、C1-4烷基或卤素；R2和R3独立地为氢、OH、C1-4烷氧基、C1-4烷基或用卤素、OH、C1-4烷氧基或CN取代的C1-4烷基；X独立地从H、卤素、C1-4烷基、卤素取代的C1-4烷基、OH、C1-4烷氧基、卤素取代的C1-4烷氧基、C1-4烷基硫醚、NO2、NH2、二-(C1-4烷基)氨基和CN中选择；n为0、1、2、3和4。 这项发明还提供了一种用于治疗前列腺素参与的医疗状况的药物组合物。
• Oxygen isosteric derivatives of 3-(3-hydroxyphenyl)-N-n-propylpiperidine
  作者：Roberto Perrone、Francesco Berardi、Marcello Leopoldo、Vincenzo Tortorella、Marcello D. Lograno、Eugenia Daniele、Stefano Govoni

  DOI：10.1021/jm00094a019

  日期：1992.8

  serotonergic receptors, in comparison with 3-PPP and its analogue 3a,b. The results show the loss of D-2 affinity for all morpholines, while a certain activity was still observable for piperidine derivatives. Regarding the serotonergic affinity, only chloro and methoxy derivatives (10a-d) were moderately active on the 5-HT1A receptor, either when the substituent was in the C-2 or C-3 position, whereas no tested

  制备了3-（3-羟基-苯基）-Nn-丙基哌啶（3-PPP）的等排物，一些取代的3-苯基吗啉（10a-e，j，k）和3-噻吩吗啉（10f，g）并提交给与3-PPP及其类似物3a，b相比，对D-2多巴胺能，5-HT1和5-HT2血清素能受体的结合测定。结果表明，D-2对所有吗啉的亲和力丧失，但哌啶衍生物仍可观察到一定的活性。关于血清素能亲和力，当取代基位于C-2或C-3位置时，只有氯和甲氧基衍生物（10a-d）对5-HT1A受体具有中等活性，而没有受试化合物对5 -HT2受体。
• [EN] PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS<br/>[FR] DERIVES DE PYRIMIDINE UTILISES EN TANT QU'ANTAGONISTES DE RECEPTEURS D'OREXINE
  申请人：SANOFI AVENTIS

  公开号：WO2005075458A1

  公开（公告）日：2005-08-18

  The present invention relates to the orexin receptor antagonists of the general formula (I), which are selective to orexin I receptors. (I) -wherein Ar stands for phenyl group or a 5- or 6-membered heterocyclic ring containing 1-3 identical or different heteroatoms or methylenedioxyphenyl group -these groups may optionally be substituted with one or more identical or different C1.4 alkyl group, halogen atom, hydroxyl group, C1-4 alkoxy group, trihalogenomethyl group, NHC1.4 alkyl, -N(CI-4 alkyl)2 or -NHC(=0)-C1-4 alkyl group,

  本发明涉及通式（I）的俄利新受体拮抗剂，这些拮抗剂对俄利新I受体具有选择性。其中，Ar代表苯基或含有1-3个相同或不同杂原子或亚甲二氧基苯基的5-或6元杂环的环，这些基团可以选择性地用一个或多个相同或不同的C1.4烷基基团、卤原子、羟基、C1-4烷氧基、三卤甲基基团、NHC1.4烷基、-N(CI-4烷基)2或-NHC(=0)-C1-4烷基基团取代。